Bisphosphonates (BPs) are commonly used in the treatment of myeloma-associated osteolytic lesions. Recent reports have suggested that BPs may also exert direct antitumor effects on myeloma cells. Here, we show that the treatment of myeloma cell lines with the combination of the potent BP zoledronate and dexamethasone inhibits cell growth and synergistically induces apoptotic cell death, providing a rationale for potential applications in vivo. Leukemia (2000) 14, 841-844.
Introduction
Multiple myeloma (MM) is associated with a high incidence of osteolytic bone destruction 1 caused by a marked increase of osteoclastic activity 2 and mediated by the tumor cell release of osteoclast-stimulating factors. 3 Bisphosphonates (BPs) are commonly used in the treatment of diseases characterized by bone resorption because of their ability to interfere with osteoclast recruitment, differentiation and action, and to induce apoptotic cell death of these cells. [4] [5] [6] Recent reports have showed that BPs may also have a direct antiproliferative effect and induce apoptosis in human myeloma cell lines in vitro 7 and in plasma cells isolated from patients with MM. 8 Clinical studies have suggested that BPs may induce a reduction of the tumor burden 9 and may prolong the survival of MM patients. 10, 11 We have evaluated if the combination of zoledronate (Zln), a potent antiresorptive BP, 12 and dexamethasone (Dex), which is commonly used in the treatment of MM, could strengthen the inhibition of cell growth and the induction of apoptosis in human myeloma cell lines in vitro. Here, we show that the combination of both agents results in synergistic anti-myeloma effects, providing a rationale for in vivo investigations on this therapeutical combination.
Materials and methods

Reagents
Zln (CGP-42446), a third-generation bisphosponate, was kindly provided by Novartis (Basel, Switzerland). Pamidronate (Pam) (3-amino-1-hydroxy-propylidene-1.1-bisphosphonate) was purchased from Novartis. Dex (Soldesam) was purchased from Laboratorio Farmacologico Milanese (Varese, Italy). IL-6 was purchased from PeproTech EC Ltd (London, UK). 
Cell culture
The IL-6-dependent myeloma cell line XG-1 13 was a generous gift of Dr B Klein (Molecular Genetics, CNRS, Montpellier, France). XG-1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 g/ml streptomycin and 100 U/ml penicillin in the presence of 2 ng/ml of IL-6 at 37°C in a 7.5-8% CO 2 atmosphere. XG-1a, an IL-6 autocrine subclone of XG-1 cell line, was generated by long-term culture of XG-1 cells in low concentrations of IL-6 (0.1 ng/ml). The U266 and the IM-9 human myeloma cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 g/ml streptomycin and 100 U/ml penicillin at 37°C in a 5% CO 2 atmosphere.
Measurement of cell proliferation
XG-1, XG-1a, U266 and IM-9 cells were seeded in 24-well plates at 3 × 10 4 /ml and 1 × 10 4 /ml, respectively. Cells were treated with Zln (or Pam) and/or Dex and viability and cell growth were measured by trypan blue exclusion and hemocytometric count after 6 days of culture. Analysis was carried out on at least three separate experiments.
Flow cytometric analysis of apoptosis
Apoptotic cell death was analyzed by the Mebstain technique, a modification of the TUNEL method, and by propidiumiodide staining (PI). The Mebstain method (Immunotech, Marseille, France) 14 measures the incorporation of fluoresceindUTP (FITC-dUTP) catalyzed by terminal deoxynucleotidyl transferase (TdT), thereby enabling the detection of DNA fragmentation in nucleosome multimers during programmed cell death. Briefly, 1 to 2 × 10 6 cells were washed and fixed with 200 l of 4% paraformaldehyde (PFA) at 4°C for 30 min. After fixation, cells were washed and permeabilized in 70% ethanol for 30 min at −20°C. Cells were washed again and resuspended in a solution containing FITC-dUTP and TdT for 1 h at 37°C. Finally, after a further washing, the cells were analyzed by flow cytometry.
PI analysis was performed as described. 15, 16 Cells were washed in PBS, incubated for 10 min in trypsin buffer and then with a trypsin inhibitor and RNase buffer for an additional 10 min. PI (CycleTEST PLUS, DNA Reagents Kit, Becton Dickinson, San Jose, CA, USA) was then added for 10 min at 4°C in the dark and cells were acquired with a FACScan flow cytometer using the CELLQuest program (Becton Dickinson). For each sample 2 × 10 4 events were acquired. Apoptotic cells were detected as a hypodiploid population. Analysis was carried out on at least three separate experiments.
Statistical analysis
Results are expressed as mean ± s.d. The statistical significance of differences between the individual and the combined treatment experimental points was analyzed using the t-test; differences were considered significant when P Ͻ 0.05. Measurement of the synergistic index (SI) was determined as previously described 17 with the following formula: SI = (effect induced by Zln and Dex in combination)/(effect of Zln) + (effect of Dex). Interactions were considered synergistic when the SI was Ͼ1.
Results and discussion
The antiproliferative effects of Zln or/and Dex on four human myeloma lines are summarized in Figure 1 . After 6 days of culture, the mean percentage of growth inhibition of the four cell lines was 45.4% in the Zln-treated cultures, and 52.1% in the cultures incubated with Dex. The combination of Zln + Dex showed a stronger inhibitory effect than either drug alone in all the cell lines studied (78.6% of inhibition). This effect was particularly pronounced in XG-1a cells (Figure 1) . Figure 2 shows the apoptotic response of myeloma cells to Zln and/or Dex. In panels a and b, a representative experiment is shown where the apoptosis was evaluated in XG-1a cells by measuring in parallel FITC-dUTP incorporation (a) and hypodiploid DNA content after labelling with PI (b). The flow cytometric analysis by the two techniques disclosed a strong similarity in the magnitude of apoptotic events and the combined treatment led to a clear synergism (SI = 2 by Mebstain; SI = 3.5 by PI; Figure 2) . Comparison between the two methods was also performed for the IM-9 cell line with similar results (SI = 1.6 by Mebstain; SI = 1.1 by PI in a parallel representative experiment). Antiproliferative effects of Zln (50 M) or/and Dex (10 M) on human myeloma cells. Cells were seeded at the concentration of 3 × 10 4 /ml (XG-1, XG-1a and U266) and 1 × 10 4 (IM-9) in the culture medium as described in Materials and methods. The number of viable cells was determined by trypan blue exclusion dye and by hemocytometric cell count after 6 days of culture. Data are expressed as mean ± s.d. of at least three separate experiments (XG-1, n = 3; XG-1a, n = 6; U266, n = 3; IM-9, n = 3). *P Ͻ 0.05 compared to Dex or Zln. Ctl, Control; Z, zoledronate; D dexamethasone. apoptosis in the four cell lines with a mean percentage of 7.3% for Zln and of 8.4% for Dex as compared with control cultures (3.9% of apoptosis). Incubation with Zln + Dex resulted in a synergistic and/or additive enhancement of apoptosis in all myeloma cell lines with a mean of 24.3% of apoptotic cells, this effect being particularly pronounced in XG-1a cells (Figure 2c ) compared with other cell lines.
The antiproliferative and apoptotic effect of Zln was compared with that of Pam, a less potent antiresorptive BP. Although high concentrations of Pam (10-fold higher than those of Zln) were used, as shown in Figure 3 the association of Zln and Dex was more effective than that of Pam and Dex in inducing cell death, with a marked difference being observed in XG-1a and U266 cells.
Thus the in vitro exposure of myeloma cell lines to the combination of Zln and Dex exerts a potent growth inhibitory effect on human myeloma cell lines, and demonstrates a synergistic induction of apoptosis. The results shown here also highlight the potential clinical value of the recently developed BP, Zln, whose combination with Dex may result in greater anti-myeloma effects, and yield benefit in the treatment of MM.
The molecular mechanisms whereby Zln enhances Dexinduced growth arrest and apoptosis of MM cells remain to be clarified. Nitrogen-containing BPs are thought to act by inhibiting enzymes of the mevalonate pathway, 18 which leads to the isoprenylation of GTP-binding proteins involved in the control of cell growth such as ras. 19 In addition, BPs may interrupt the release of growth factors, including IL-6, 20,21 by osteoclasts and osteoblasts, which in turn promote myeloma cell proliferation and survival, and the secretion of osteoclast-stimulating factors. 22 BPs may also suppress IL-6 production by bone marrow stromal cells (BMSCs). 23 The stronger effect induced by the combination of Zln and Dex on XG-1a as compared to XG-1, U266 and IM-9, might be explained as a selective interference with the IL-6 autocrine behavior of the former cell line.
It is worth noting to emphasize that IL-6 is the major growth factor for MM 24 and also protects myeloma cells from apoptosis induced by Dex. 25, 26 In vivo BPs accumulate within exposed bone mineral around resorbing osteoclasts, therefore the pharmacological doses that are currently used for the inhibition of bone resorption could give rise to very high local concentrations, up to 1 mM, in the resorption lacunae. 27 Since the areas of active bone resorption have been described as specific homing sites of MM cells, 2 the tumor cells may be exposed to a relatively high concentration of these antiresorptive agents. In this scenario, BPs may potentiate in vivo the therapeutic action of Dex on myeloma cells (1) through direct antiproliferative and apoptotic effects, and (2) by the inhibition of paracrine and autocrine IL-6 production by BMSCs, osteoclasts, osteoblasts and MM cells.
The results described in this study, once substantiated by in vivo data, could provide a rationale for the treatment of MM patients with Zln and Dex and suggest that the combination of these drugs, both of which are individually used in the treatment of MM, could be of clinical relevance. 
